What Is IGF-1? Biology, Testing, and Clinical Evidence

Understand IGF-1 biology, growth hormone regulation, binding proteins, lab interpretation, FDA-approved mecasermin use, and the limits of IGF-1 LR3 claims.

Insulin-like growth factor 1, or IGF-1, is a hormone and growth factor involved in normal childhood growth, tissue development, and metabolism. Growth hormone stimulates much of the IGF-1 found in circulation, while many tissues also produce IGF-1 for local signaling.

IGF-1 is not a universal score for vitality, muscle gain, or longevity. A blood result must be interpreted against an age-adjusted reference range and the person's clinical context. Native IGF-1, the prescription drug mecasermin, and the research analog IGF-1 LR3 are also not interchangeable.

IGF-1 at a glance

Question	Evidence-based answer
What is native human IGF-1?	A single-chain protein containing 70 amino acids and three intramolecular disulfide bridges
Where does circulating IGF-1 come from?	Primarily the liver, in response to growth hormone; other tissues also produce IGF-1 locally
What receptor does it activate?	Mainly the type 1 IGF receptor, or IGF-1R, a receptor tyrosine kinase
Why do binding proteins matter?	Six high-affinity IGF-binding proteins influence transport, half-life, and access to tissues
What does an IGF-1 blood test show?	A relatively stable marker of the growth hormone–IGF-1 axis that requires age-, assay-, and context-specific interpretation
Is an IGF-1 drug FDA-approved?	Mecasermin is approved for narrowly defined pediatric growth failure—not for general wellness, anti-aging, bodybuilding, or athletic recovery
Is IGF-1 LR3 FDA-approved?	No FDA-approved IGF-1 LR3 drug or therapeutic indication was identified at this review date

Regulatory status and prescribing-label details are current through August 29, 2026 in the United States.

The growth hormone–IGF-1 axis

The axis starts in the brain and pituitary gland:

The hypothalamus regulates pituitary growth hormone release through signals that include growth hormone-releasing hormone and somatostatin.
Growth hormone enters circulation and binds growth hormone receptors in the liver and other tissues.
The liver releases IGF-1 into the bloodstream. Tissues also make IGF-1 for local autocrine and paracrine signaling.
IGF-1 binds receptors on target cells and helps coordinate growth and metabolic processes.
Growth hormone and IGF-1 participate in feedback that helps regulate the axis.

Growth hormone secretion is pulsatile and changes during the day. IGF-1 is more stable in circulation, which is why clinicians often measure it when evaluating suspected growth hormone excess or deficiency. Stability does not make the result diagnostic by itself.

How IGF-1 signaling works

IGF-1 primarily activates IGF-1R. Once activated, that receptor can recruit intracellular signaling proteins and engage pathways including:

PI3K–AKT–mTOR, which participates in cell metabolism, protein synthesis, and survival signaling; and
RAS–MAPK, which participates in cell proliferation, migration, and differentiation.

These pathways help explain why IGF-1 is important in normal biology. They do not prove that administering IGF-1 will heal an injury, build muscle, improve cognition, prevent aging, or treat a disease. Receptor activity in cells or animals is an early evidence layer, not a clinical outcome in humans.

Binding proteins change IGF-1 availability

Most circulating IGF-1 is bound rather than free. Six high-affinity insulin-like growth factor-binding proteins, IGFBP-1 through IGFBP-6, can prolong IGF exposure and regulate how much ligand reaches receptors.

The current FDA label for mecasermin states that more than 80% of circulating IGF-1 is carried in a complex with IGFBP-3 and an acid-labile subunit. Binding-protein concentrations vary with growth hormone status and other physiologic conditions, so the same total IGF-1 concentration does not necessarily describe identical tissue exposure in every person.

What an IGF-1 blood test can—and cannot—show

An IGF-1 result is usually compared with a laboratory reference interval or a standard-deviation score matched to age. Values commonly decline across adulthood, and results can also be influenced by nutrition, liver function, kidney disease, glucose regulation, body composition, pregnancy, medications, acute illness, and the assay used.

A high result

A high age-adjusted IGF-1 result can support an evaluation for growth hormone excess. The National Institute of Diabetes and Digestive and Kidney Diseases explains that a high IGF-1 level usually suggests acromegaly, but diagnosis is not based on that result alone. Clinicians may confirm the finding, measure growth hormone response during an oral glucose tolerance test, review symptoms and medications, and use pituitary imaging when appropriate.

A low result

A low result can occur with growth hormone deficiency, but also with malnutrition, liver disease, poorly controlled diabetes, hypothyroidism, chronic illness, and other conditions. In adults, symptoms such as fatigue or changes in body composition plus one low IGF-1 value do not establish growth hormone deficiency. Testing is guided by clinical history, other pituitary findings, and—in many patients—a validated growth hormone stimulation test.

No universal optimization target

Observational studies have reported higher mortality at both low and high IGF-1 concentrations relative to middle categories. That U-shaped association does not show that deliberately moving an individual toward a particular number improves health or extends life. Cohort cutoffs vary, assays differ, and association is not proof of an effective intervention.

What the evidence supports

Research question	Evidence level	What can reasonably be concluded?
Does IGF-1 participate in normal growth and development?	Established human physiology	Yes. It is a key mediator of growth hormone action and statural growth.
Can recombinant human IGF-1 treat severe primary IGF-1 deficiency?	FDA-reviewed product evidence	Mecasermin has a narrow pediatric indication for defined severe primary IGF-1 deficiency and a second rare GH-antibody population.
Can IGF-1 help evaluate the growth hormone axis?	Established clinical use	Yes, as one contextual marker. It is useful in acromegaly evaluation and can support deficiency workups, but it is not universally diagnostic alone.
Does IGF-1 signaling affect muscle, bone, cartilage, brain, and metabolism?	Strong mechanistic and preclinical evidence	Yes biologically, but mechanism alone does not establish a safe or effective treatment for injury, cognition, osteoporosis, diabetes, or body composition.
Does raising IGF-1 slow aging or improve longevity?	Mixed observational and preclinical evidence	No anti-aging benefit has been established. Both low and high levels can be associated with risk, and no general optimization target is validated.
Does IGF-1 LR3 improve performance or recovery in people?	Insufficient therapeutic evidence	Mechanistic claims and research-product descriptions do not establish clinical benefit, safe dosing, or long-term safety.

FDA-approved IGF-1 treatment is narrow

Mecasermin is recombinant human IGF-1 with the same 70-amino-acid sequence as endogenous human IGF-1. The current FDA prescribing label for Increlex limits use to growth failure in children age 2 years and older with:

severe primary IGF-1 deficiency; or
growth hormone gene deletion with neutralizing antibodies to growth hormone.

The label explicitly says mecasermin is not a substitute for growth hormone in approved growth hormone indications. It is not indicated for secondary low IGF-1 caused by growth hormone deficiency, malnutrition, hypothyroidism, or chronic use of pharmacologic corticosteroid doses.

This is a prescription therapy requiring specialist supervision. The label includes contraindications and warnings for hypoglycemia, hypersensitivity and anaphylaxis, intracranial hypertension, enlarged tonsillar or adenoidal tissue, slipped capital femoral epiphysis, progression of scoliosis, and malignant neoplasia. Those are product-specific safety facts, not a self-treatment checklist.

Native IGF-1, mecasermin, and IGF-1 LR3 are different

Name	What it is	Regulatory and evidence context
Native IGF-1	The endogenous 70-amino-acid human hormone	Normal physiology and the analyte measured in clinical blood testing
Mecasermin	Recombinant human IGF-1 with the native sequence	FDA-approved as Increlex for narrow pediatric populations under a prescribing label
IGF-1 LR3	An engineered IGF-1 research analog designed to alter interaction with IGF-binding proteins	Not an FDA-approved medicine; no established therapeutic dose, cycle, or long-term safety profile

Research-product claims about IGF-1 LR3 potency or duration should not be borrowed from mecasermin labeling. A modification that changes binding-protein interaction can also change exposure and risk; it does not demonstrate a better clinical treatment. This guide therefore does not provide IGF-1 LR3 dosing or cycling instructions.

Common claims that exceed the evidence

The earlier version of this guide listed IGF-1 as a treatment or performance aid for sports injuries, heart failure, diabetes, weight loss, brain health, inflammation, bone density, and aging. The available evidence does not support presenting those as established uses.

Three errors commonly create that overstatement:

Mechanism becomes a treatment claim. A pathway involved in tissue growth does not prove that adding a growth factor improves a patient-important outcome.
Association becomes causation. A low or high biomarker observed alongside disease does not show that changing the biomarker treats the disease.
One molecule is substituted for another. Native IGF-1 physiology, labeled mecasermin data, and an engineered research analog are not interchangeable evidence.

A practical research checklist

Before accepting an IGF-1 claim, ask:

Which molecule was studied? Endogenous IGF-1, mecasermin, and IGF-1 LR3 are different exposures.
What evidence layer supports the statement? Cell signaling, animal models, observational associations, and randomized human outcomes answer different questions.
Does the population match the claim? Pediatric severe primary IGF-1 deficiency does not establish use in healthy adults.
Was the outcome clinical or only a biomarker? A change in IGF-1 concentration does not automatically mean better function, recovery, or survival.
Was the result interpreted against the right reference range? Age, assay, health status, and clinical history matter.
Is the finished product verified? A label for an FDA-approved drug does not validate a product sold as a research chemical.

Frequently asked questions

Is IGF-1 the same as growth hormone?

No. Growth hormone is released by the pituitary gland and stimulates IGF-1 production in the liver and other tissues. IGF-1 mediates some—but not all—growth hormone effects. The sermorelin versus HGH comparison maps the upstream portion of this axis.

Is IGF-1 the same as insulin?

No. They are structurally related signaling proteins with related receptors, but they have distinct physiologic roles. IGF-1 can affect glucose metabolism, and mecasermin can cause serious hypoglycemia, but IGF-1 is not a replacement for insulin.

What does a high IGF-1 result mean?

It can support suspicion of growth hormone excess, including acromegaly, when elevated for the person's age and clinical context. A clinician may repeat or confirm testing and use additional biochemical and imaging tests rather than diagnose from one number.

What does a low IGF-1 result mean?

It can be consistent with growth hormone deficiency, severe primary IGF-1 deficiency, undernutrition, liver disease, hypothyroidism, poorly controlled diabetes, or other illness. Interpretation depends on age, symptoms, medical history, other pituitary hormones, and sometimes stimulation testing.